Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis.

Bile Duct Neoplasms / etiology Cholangiocarcinoma / etiology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use

Journal

Journal of gastrointestinal and liver diseases : JGLD
ISSN: 1842-1121
Titre abrégé: J Gastrointestin Liver Dis
Pays: Romania
ID NLM: 101272825

Informations de publication

Date de publication:
13 Dec 2020
Historique:
received: 03 09 2020
accepted: 16 10 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 13 10 2021
Statut: epublish

Résumé

The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together. A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird. A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%). The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.
METHODS METHODS
A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
RESULTS RESULTS
A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).
CONCLUSIONS CONCLUSIONS
The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

Identifiants

DOI: 10.15403/jgld-2990 PMID: 33331334
pubmed: 33331334
doi: 10.15403/jgld-2990
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

629-635

Auteurs

Karn Wijarnpreecha (K)

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States. dr.karn.wi@gmail.com.

Elizabeth S Aby (ES)

Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota, United States. abyxx002@umn.edu.

Hassan Ghoz (H)

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States. ghoz.hassan@mayo.edu.

Wisit Cheungpasitporn (W)

Department of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, United States. wcheungpasitporn@gmail.com.

Frank J Lukens (FJ)

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States. lukens.frank@mayo.edu.

Denise M Harnois (DM)

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States. harnois.denise@mayo.edu.

Patompong Ungprasert (P)

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, United States. p.ungprasert@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil digestif › Tumeurs de l'appareil digestif › Tumeurs des voies biliaires › Tumeurs des canaux biliaires › Statins and Risk of Cholangiocarcinoma: A...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Cholangiocarcinome › Statins and Risk of Cholangiocarcinoma: A...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Statins and Risk of Cholangiocarcinoma: A...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase › Statins and Risk of Cholangiocarcinoma: A...